A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.
- Registry ID
- EUCTR2019-001318-40
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE2
- Sponsor
- Starpharma Pty Ltd
- Start date
- 2019-06-18
- Last update
- 2026-08-16
Conditions
Summary
To establish the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of SN38-SPL9111 given intravenously (IV)
Locations
View on source registry